Cargando…
Reversal of P-glycoprotein-mediated multidrug resistance by XR9051, a novel diketopiperazine derivative.
XR9051 (N-(4-(2-(6,7-Dimethoxy-1,2,3,4-tetrahydro-2-isoquinolyl)ethyl)phe nyl)-3-((3Z,6Z)-6-benzylidene-1-methyl-2,5-dioxo-3-pipera zinylidene) methylbenzamide) was identified as a potent modulator of P-glycoprotein-mediated multidrug resistance (MDR) following a synthetic chemistry programme based...
Autores principales: | Dale, I. L., Tuffley, W., Callaghan, R., Holmes, J. A., Martin, K., Luscombe, M., Mistry, P., Ryder, H., Stewart, A. J., Charlton, P., Twentyman, P. R., Bevan, P. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group|1
1998
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063130/ https://www.ncbi.nlm.nih.gov/pubmed/9764579 |
Ejemplares similares
-
In vivo efficacy of XR9051, a potent modulator of P-glycoprotein mediated multidrug resistance
por: Mistry, P, et al.
Publicado: (1999) -
Antitumour activity of XR5944 in vitro and in vivo in combination with 5-fluorouracil and irinotecan in colon cancer cell lines
por: Harris, S M, et al.
Publicado: (2005) -
Retention of activity by selected anthracyclines in a multidrug resistant human large cell lung carcinoma line without P-glycoprotein hyperexpression.
por: Coley, H. M., et al.
Publicado: (1991) -
Non-P-glycoprotein-mediated multidrug resistance with reduced EGF receptor expression in a human large cell lung cancer cell line.
por: Reeve, J. G., et al.
Publicado: (1990) -
Interaction of tamoxifen with the multidrug resistance P-glycoprotein.
por: Callaghan, R., et al.
Publicado: (1995)